PharmaCyte Biotech Inc (PMCB)

[TPX]

PMCB News! PharmaCyte Biotech to Hold Shareholder Call

LAGUNA HILLS, Calif., Jan. 18, 2017 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that Chief Executive Officer Kenneth L. Waggoner will conduct a shareholder conference call at 4:30 p.m. EST on Tuesday, February 7, 2017.

Commenting on the upcoming shareholder conference call, Mr. Waggoner said, “After what can only be described as a landmark moment in PharmaCyte’s history, we are excited to report on what was a positive pre-IND meeting with the U.S. FDA. We made excellent progress and received good advice and guidance toward the goal of filing our IND. We now have a clear path forward, and we will use this upcoming shareholder call to lay out that path for analysts, shareholders and the public.”

Management will provide the latest information to analysts and shareholders about PharmaCyte's upcoming clinical trial in locally advanced, inoperable pancreatic cancer (LAPC), the company’s interaction with the U.S. Food and Drug Administration (FDA) and respond to written questions. Analysts and shareholders are requested to submit questions they may have about PharmaCyte’s clinical development program via email to [e-mail]. Mr. Waggoner will respond to as many of the questions as possible in the time permitted for the call.

Date: February 7, 2017
Time: 4:30 p.m. EST
Telephone Number: [phone]
Access Code: 915-603-449
Once the call has been completed, an audio replay will be available to the public. PharmaCyte will provide a telephone number and access code to listen to the recorded call.

https://globenewswire.com/news-release/2017/01/18/906672/0/en/PharmaCyte-Biotech-to-Hold-Shareholder-Call.html